Kharazmi et al., 2023 - Google Patents
Gallstones, cholecystectomy, and kidney cancer: observational and mendelian randomization results based on large cohortsKharazmi et al., 2023
View HTML- Document ID
- 17955423788142983553
- Author
- Kharazmi E
- Scherer D
- Boekstegers F
- Liang Q
- Sundquist K
- Sundquist J
- Fallah M
- Bermejo J
- Publication year
- Publication venue
- Gastroenterology
External Links
Snippet
Background & Aims Gallstones (cholelithiasis) constitute a major health burden with high costs related to surgical removal of the gallbladder (cholecystectomy), generally indicated for symptomatic gallstones. The association between gallstones and cholecystectomy and …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kharazmi et al. | Gallstones, cholecystectomy, and kidney cancer: observational and mendelian randomization results based on large cohorts | |
Escala-Garcia et al. | Breast cancer risk factors and their effects on survival: a Mendelian randomisation study | |
Udler | Type 2 diabetes: multiple genes, multiple diseases | |
Markt et al. | Circadian clock genes and risk of fatal prostate cancer | |
Grzych et al. | NASH-related increases in plasma bile acid levels depend on insulin resistance | |
Yang et al. | Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer | |
Park et al. | A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes | |
Andreotti et al. | Serum lipid levels and the risk of biliary tract cancers and biliary stones: a population‐based study in China | |
Ning et al. | Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts | |
Schieffer et al. | Reduced total serum bilirubin levels are associated with ulcerative colitis | |
Dierckx et al. | GlycA, a nuclear magnetic resonance spectroscopy measure for protein glycosylation, is a viable biomarker for disease activity in IBD | |
Klar et al. | Phenotypic expansion of visceral myopathy associated with ACTG2 tandem base substitution | |
Li et al. | Correlation between alterations of gut microbiota and miR-122-5p expression in patients with type 2 diabetes mellitus | |
Billings et al. | Impact of common variation in bone-related genes on type 2 diabetes and related traits | |
Pezzolesi et al. | An intergenic region on chromosome 13q33. 3 is associated with the susceptibility to kidney disease in type 1 and 2 diabetes | |
Hur et al. | Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity | |
Power et al. | Serum zonulin measured by commercial kit fails to correlate with physiologic measures of altered gut permeability in first degree relatives of crohn's disease patients | |
Indika et al. | Many pitfalls in diagnosis of acute intermittent porphyria: a case report | |
Wu et al. | Measurement of gut microbial metabolites in cardiometabolic health and translational research | |
Zhen et al. | Genome-wide association and Mendelian randomisation analysis among 30,699 Chinese pregnant women identifies novel genetic and molecular risk factors for gestational diabetes and glycaemic traits | |
Dong et al. | Duodenal microbiome and serum metabolites predict hepatocellular carcinoma in a multicenter cohort of patients with cirrhosis | |
Hao et al. | Integrative genome-wide analyses identify novel loci associated with kidney stones and provide insights into its genetic architecture | |
Vaughan-Shaw et al. | Oral vitamin D supplementation induces transcriptomic changes in rectal mucosa that are linked to anti-tumour effects | |
Kim et al. | Molecular diagnosis of glycogen storage disease type IX using a glycogen storage disease gene panel | |
Pan et al. | Distinct common signatures of gut microbiota associated with damp-heat syndrome in patients with different chronic liver diseases |